FDA Grants GSK's Advair Broader Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-selling asthma drug cleared for COPD flare-ups.
You may also be interested in...
Spiriva Finds COPD Exacerbation Studies Can Be An Exasperating Experience
As competitors tout comparative data, Boehringer hopes a Nov. 19 advisory committee on its claim for reduction in exacerbations will lead to a broader label.
Spiriva Finds COPD Exacerbation Studies Can Be An Exasperating Experience
As competitors tout comparative data, Boehringer hopes a Nov. 19 advisory committee on its claim for reduction in exacerbations will lead to a broader label.
AstraZeneca Wants COPD Label For Symbicort
Newly reported trials prove safety and efficacy, company says.